Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex.
Members of the Mycobacterium avium complex are the most frequently encountered opportunistic bacterial pathogens among patients in the advanced stage of AIDS. Two clinical isolates of the same strain, numbers 397 and 417, were obtained from an AIDS patient with disseminated M. avium complex infection before and after treatment with a regimen of clarithromycin and ethambutol. To identify the biochemical consequence of drug treatment, the expression and chemical composition of their major cell wall constituents, the arabinogalactan, lipoarabinomannan, and the surface glycopeptidolipids (GPL), were critically examined. Through thin layer chromatography, mass spectrometry, and chemical analysis, it was found that the GPL expression profiles differ significantly in that several apolar GPLs were overexpressed in the clinically resistant 417 isolate at the expense of the serotype 1 polar GPL, which was the single predominant band in the ethambutol-susceptible 397 isolate. Thus, instead of additional rhamnosylation on the 6-deoxytalose (6-dTal) appendage to give the serotype 1-specific disaccharide hapten, the accumulation of this nonextended apolar GPL probably provided more precursor substrate available for further nonsaccharide substitutions including a higher degree of O-methylation to give 3-O-Me-6-dTal and the unusual 4-O-sulfation on 6-dTal. Further data showed that this alteration effectively neutralized ethambutol, which is known to inhibit arabinan synthesis. Thus, in contrast with derived Emb-resistant mutants of Mycobacterium smegmatis or Mycobacterium tuberculosis, which are devoid of a surface GPL layer, the lipoarabinomannan from resistant 417 isolate grown in the presence of this drug was not apparently truncated.
Khoo
K H
KH
Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan, Republic of China.
Jarboe
E
E
Barker
A
A
Torrelles
J
J
Kuo
C W
CW
Chatterjee
D
D
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002473:Cell Wall / Q000737:chemistry / Q000378:metabolism; D002855:Chromatography, Thin Layer; D017291:Clarithromycin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D005685:Galactans / Q000096:biosynthesis; D006001:Glycoconjugates / Q000096:biosynthesis*; D006801:Humans; D008070:Lipopolysaccharides / Q000096:biosynthesis; D013058:Mass Spectrometry; D015269:Mycobacterium avium Complex / Q000378:metabolism*; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy / Q000378:metabolism* / Q000382:microbiology; D011134:Polysaccharides / Q000096:biosynthesis; D011135:Polysaccharides, Bacterial / Q000096:biosynthesis; D013499:Surface Properties
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D005685:Galactans; D006001:Glycoconjugates; D008070:Lipopolysaccharides; D011134:Polysaccharides; D011135:Polysaccharides, Bacterial; C050016:lipoarabinomannan; C030080:araban; D004977:Ethambutol; D017291:Clarithromycin; C005653:arabinogalactan